

## Special Issue

# Immunotherapy for Renal Cell Carcinoma

### Message from the Guest Editors

Renal cell carcinoma (RCC) is a heterogeneous disease with at least 16 histopathological subtypes identified to date. Recent genomic data have demonstrated high molecular heterogeneity in renal cell carcinoma (RCC). The pathophysiology of RCC is complex and arises from a combination of gene mutations (i.e., VHL, PBM1, SETD2, BAP1, etc.) in addition to other factors such as diabetes, obesity, smoking, and hypertension. The current backbone for the treatment of renal cell carcinoma (RCC) includes VEGF inhibitors, mTOR inhibitors and checkpoint inhibitors (CPI) targeting PD/PD-L1 and CTLA4. In the past few years, the combination of VEGF inhibitors and CPI have shown significant improvement in the outcomes of RCC. Additionally, the role of HIF inhibitors is evolving and is being evaluated in numerous clinical trials. The aim of this Special Issue is to provide a comprehensive overview of the impact of RCC development and progression by considering their association with key features of RCC, namely microenvironment, drug resistance, metabolism, angiogenesis, metastatic process, and immune response.

---

### Guest Editors

Dr. Yousef Zakharia

Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA

Dr. Rohan Garje

Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA

---

### Deadline for manuscript submissions

closed (15 June 2022)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 7.8  
Indexed in PubMed



[mdpi.com/si/86629](https://mdpi.com/si/86629)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 7.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).